Genflow Biosciences PLC Company Share Purchase by CEO

TIDMGENF

RNS Number : 9885V

Genflow Biosciences PLC

15 August 2022

15 August 2022

Genflow Biosciences Plc

("Genflow" or "the Company")

Company Share Purchase by CEO

Genflow Biosciences (LSE: GENF) , a UK-based biotechnology company focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with advanced age,

announces that it was notified on 08 August 2022, that Eric Leire, a director of the Company, purchased the following Ordinary Shares:

 
 PDMR / Person          Total Number        Weighted         Resultant       Percentage 
  closely associated     of Ordinary         Average Price    Shareholding    Of The Total 
                         Shares Purchased    per Ordinary                     Voting Rights 
                                             Share                            of the Company 
 Eric Leire             106,000             0.028            120,414,999     41.17 
                       ------------------  ---------------  --------------  ---------------- 
 

Notifications have been made in accordance with the requirements of the EU Market Abuse Regulation in respect of the PDMRs and further details can be found by following this link:

https://genflowbio.com/investors/news-releases/

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

For further information please contact:

 
 Genflow Biosciences 
 Dr Eric Leire                         via Tancredi [phone] 
  Chief Executive 
                                      ------------------------------ 
 Clear Capital 
                                      ------------------------------ 
 
 Corporate Broker 
                                         [phone] 
  Jonathan Critchley 
  Keith Swann                            [phone] 
                                      ------------------------------ 
 Tancredi Intelligent Communication 
  Media Relations 
                                      ------------------------------ 
 Salamander Davoudi                    [phone] 
  Helen Humphrey                        [phone] 
  Benedetta Negri da Oleggio            [phone] 
                                        [e-mail] 
                                      ------------------------------ 
 

About Genflow Biosciences

Genflow is a UK-based biotechnology company established in 2020. The Company is developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases. This will be done through novel therapeutics targeting aging in humans by using adeno-associated virus ("AAV") vectors to deliver copies of the Sirtuin-6 ("SIRT6") gene variant that is found in centenarians into cells.

Its mission is to increase our understanding of the factors that control and impact lifespan. Genflow researchs, develops, and commercialises therapeutic solutions to lengthen health span, the amount of time we live in good health, creating biological interventions that enable longer and healthier lives. Genflow is dedicated to the development and commercialisation of novel therapeutics targeting aging in dogs and humans. By treating aging, Genflow can contribute to a decrease in healthcare costs and lessen the emotional and societal burden that comes with an aging population.

To learn more visit www.genflowbio.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHGPURPRUPPUAA

(END) Dow Jones Newswires

August 15, 2022 02:00 ET (06:00 GMT)